Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 2/20 | 0.36 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.36 |
| ▸ | LARS1 | Q9P2J5 | 2/20 | 0.33 |
| ▸ | NQO2 | P16083 | 1/20 | 0.31 |
| ▸ | ERN1 | O75460 | 1/20 | 0.31 |
| ▸ | CSF1R | P07333 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31466923 | 0.83 | LPL (0.37) | LPLLIPGCSF1REGFR | |
| SCHEMBL25871728 | 0.83 | LPL (0.37) | LPLLIPGCSF1REGFR | |
| SCHEMBL15796063 | 0.78 | LPL (0.37) | LPLLIPGCSF1REGFRKDM4E | |
| SCHEMBL30278920 | 0.78 | ALDH1A1 (0.40) | LPLLIPGKDM4EALDH1A1 | |
| SCHEMBL26058390 | 0.78 | LPL (0.38) | LPLLIPGCSF1REGFR | |
| SCHEMBL29012935 | 0.78 | LPL (0.38) | LPLLIPGCSF1REGFRALDH1A1 | |
| SCHEMBL20508307 | 0.77 | LPL (0.40) | LPLLIPGCSF1REGFR | |
| SCHEMBL30385846 | 0.77 | LPL (0.40) | LPLLIPGCSF1REGFR | |
| SCHEMBL21272121 | 0.76 | EGFR (0.38) | LPLLIPGCSF1REGFRKDM4E | |
| SCHEMBL25311940 | 0.76 | KDM4E (0.35) | LPLLIPGKDM4EALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150315127-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2015-11-05 | — | — | US | disclosed |
| US-20150315127-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2015-11-05 | — | — | US | disclosed |
| US-9024071-B2 | Therapeutic compounds | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-9024071-B2 | Therapeutic compounds | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-20100179109-A1 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. | 2010-07-15 | — | — | US | disclosed |
| US-20100179109-A1 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. | 2010-07-15 | — | — | US | disclosed |
| WO-2008124575-A1 | RENIN INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179109-A1 | RENIN INHIBITORS | REN, ACE, AGTR1 | LPL 603/4885LIPG 136/4885LARS1 2985/4885 |
| US-20150315127-A1 | THERAPEUTIC COMPOUNDS | HTR2C, GRK2, GRK3 | LPL 2017/4885LIPG 1774/4885LARS1 4374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.